Orion Acquisition Corp. Announces Appointment of Stephen Schlegel to Board of Directors

NEW YORK--(BUSINESS WIRE)--Orion Acquisition Corp. (the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced the appointment of Stephen Schlegel as a new member to the Board of Directors, effective immediately.

Mr. Schlegel, 59, served as head of Corporate Development at Anthem, Inc., a leading health benefits company, from August 2005 to February 2021 where he was responsible for leading all the company’s corporate development activities, including managing mergers and acquisitions and corporate negotiations. Prior to that, Mr. Schlegel served as Vice President, Corporate Development and Strategy at Sprint from 1998 to 2005. Mr. Schlegel is currently a member of the board of directors of American Well Corp., where here serves as Chairman of the Audit Committee and is a member of the Compensation Committee. Mr. Schlegel holds a BA in accounting from Loras College and an MBA from the University of Chicago Booth School of Business.

Mr. Schlegel joins current board members Randy Simpson, Beau Garverick, Kenneth Burdick and Rhonda Mims.

While Orion Acquisition Corp. may pursue an initial business combination target in any business or industry, the Company intends to target companies in the healthcare industry in the U.S. or other developed countries. The Company is led by Kenneth Burdick as Board Chairman, Beau Garverick as Co-Founder, Chief Executive Officer and Board Director and Randy Simpson as Co-founder and Board Director. The Company has also partnered with Halle Capital Management, a growth equity investment firm.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

About Orion Acquisition Corp.

Orion Acquisition Corp. is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in the healthcare industry. We are a unique collective of former CEOs, CFOs, and Heads of Corporate Development & Investor Relations from Fortune 200 healthcare companies, coupled with individuals that possess extensive expertise investing in publicly traded healthcare enterprises.